Program
selatogrel
Also written as “Selatogrel”, “ACT-246475” and “Selatogrel 8 mg”.
Its studies are mostly in Myocardial Infarction · Coronary Artery Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 101 open or running | phase 3since Jun 28, 2021 | Dec 20, 2017 | Jul 2027phase 3 · NCT04957719 |
| Idorsia Pharmaceuticals | 10 open or running | phase 1since Sep 27, 2013 | Sep 27, 2013 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 27, 2013First study: phase 1 study in Safety, Tolerability, Pharmacokinetics and PharmacodynamicsNew to Idorsia PharmaceuticalsIdorsia Pharmaceuticals · NCT01954615 · 49 enrolled · France
- Dec 20, 2017Viatris's first study: phase 2 study in Stable Coronary Artery DiseaseNew to ViatrisViatris · NCT03384966 · 346 enrolled · United States, Canada, Denmark and more
- Jan 30, 2018Phase 1 study in HealthyViatris · NCT03430661 · 77 enrolled · United States
- Mar 26, 2018Phase 2 study in Acute Myocardial InfarctionViatris · NCT03487445 · 48 enrolled · Belgium, Israel, Switzerland
- Jul 10, 2018Phase 1 study in Healthy SubjectsViatris · NCT03593278 · 6 enrolled · Germany
- Jan 21, 2019Phase 1 study in Healthy SubjectViatris · NCT03814200 · 14 enrolled · Netherlands
- May 25, 2020Phase 1 study in Healthy SubjectsViatris · NCT04406896 · 24 enrolled · Germany
- Sep 7, 2020Phase 1 study in Healthy SubjectsViatris · NCT04557280 · 24 enrolled · United States
- Jun 28, 2021Phase 3 study in Acute Myocardial InfarctionViatris · NCT04957719 · 25,000 planned · United States, Australia, Austria and more
- Aug 13, 2025Phase 1 study in Healthy VolunteersViatris · NCT07133191 · 32 enrolled · United States
- May 22, 2026Phase 1 study in Chronic Coronary SyndromeViatris · NCT07615868 · 20 enrolled · China
Ahead
- Jul 2027Primary completion: phase 3 study in Acute Myocardial InfarctionViatris · NCT04957719
TargetBeta
“Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule
Other programs on P2RY12
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Clopidogrelrule | Sanofi | phase 4 | 71 |
| Ticagrelorrule | AstraZeneca | phase 4 | 47 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07615868Chronic Coronary Syndrome · China | 1 | Completed | Viatris | Sep 19, 2026 | 20 |
| NCT07133191Healthy Volunteers · United States | 1 | Completed | Viatris | Nov 5, 2025 | 32 |
| NCT04957719Acute Myocardial Infarction · United States, Australia, Austria and more | 3 | By invitation | Viatris | Jul 2027 | 25,000 |
| NCT04557280Healthy Subjects · United States | 1 | Completed | Viatris | Dec 19, 2020 | 24 |
| NCT04406896Healthy Subjects · Germany | 1 | Completed | Viatris | Oct 23, 2020 | 24 |
| NCT03814200Healthy Subject · Netherlands | 1 | Completed | Viatris | Feb 12, 2019 | 14 |
| NCT03593278Healthy Subjects · Germany | 1 | Completed | Viatris | Aug 5, 2018 | 6 |
| NCT03487445Acute Myocardial Infarction · Belgium, Israel, Switzerland | 2 | Completed | Viatris | Nov 10, 2018 | 48 |
| NCT03430661Healthy · United States | 1 | Completed | Viatris | May 20, 2019 | 77 |
| NCT03384966Stable Coronary Artery Disease · United States, Canada, Denmark and more | 2 | Completed | Viatris | Aug 18, 2018 | 346 |
| NCT01954615Safety, Tolerability, Pharmacokinetics and Pharmacodynamics · France | 1 | Completed | Idorsia Pharmaceuticals | Mar 2012 | 49 |
How it is read
Names in the registry
- “Selatogrel”, 8 entries
- “ACT-246475”, 3 entries
- “Selatogrel 8 mg”, 1 entry
- “Selatogrel 16 mg”, 1 entry
- “ACT-246475 (Group G dose to be defined)”, 1 entry
Conditions, from the studies’ own filings
- Myocardial Infarction, 2 studies
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.